Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Joseph Haas
Emerging Company Profile: HemoShear thinks its REVEAL-tx platform can identify novel targets and validate drug candidates better than existing bench research methods. Japan’s Takeda is betting in a new collaboration that HemoShear can deliver novel targets in NASH.
With a successful end-of-Phase II meeting with FDA concluded, Cara moves closer to bringing the first drug to market for pruritus in ESRD patients on dialysis.
Following Gilead's acquisition of Kite, buzz grew that the deal might catalyze a surge in deal-making. Scrip asked a broad cross-section of biopharma insiders and observers about the deal-making environment – first up are responses from small biotechs.
Janssen hasn’t released Phase III data yet but says the next-generation androgen receptor inhibitor showed potential benefit for metastasis-free survival.
AbbVie takes options on three oncolytic virus immunotherapies under development at Turnstone. Amgen and CytomX swap IP in cancer immunotherapy collaboration, while Nicox and pSivida will team to fight glaucoma and other eye diseases.
A JAMA editorial asks whether mergers of academic institutions with non-academic health providers could undermine the perceived value of medical research.